Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth

European Journal of Cancer

Volumn 48, Issue 16, 2012, Pages 3093-3103

  Lamers, Fieke ^a   Schild, Linda ^a   Den Hartog, Ilona J M ^a   Ebus, Marli E ^a   Westerhout, Ellen M ^a   Ora, Ingrid ^b   Koster, Jan ^a   Versteeg, Rogier ^a   Caron, Huib N ^a   Molenaar, Jan J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LUND UNIVERSITY   (Sweden)

Author keywords

ABT263; Apoptosis; BCL2; Cancer; Neuroblastoma

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; LENTIVIRUS VECTOR; MESSENGER RNA; NAVITOCLAX; PROTEIN BCL 2; SHORT HAIRPIN RNA; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, MESSENGER; SULFONAMIDES; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867575920     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.037     Document Type: Article

References (42)

1. K.W. Yip, and J.C. Reed Bcl-2 family proteins and cancer Oncogene 27 2008 6398 6406
2. A. Frenzel, F. Grespi, W. Chmelewskij, and A. Villunger Bcl2 family proteins in carcinogenesis and the treatment of cancer Apoptosis 14 2009 584 596
3. D. Yecies, N.E. Carlson, J. Deng, and A. Letai Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1 Blood 115 2010 3304 3313
4. A. Egle, A.W. Harris, M.L. Bath, L. O'Reilly, and S. Cory VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia Blood 103 2004 2276 2283
5. M. Vogler, D. Dinsdale, M.J.S. Dyer, and G.M. Cohen Bcl-2 inhibitors: small molecules with a big impact on cancer therapy Cell Death Differ 16 2009 360 367
6. L. Zhang, L. Ming, and H. Yu BH3 mimetics to improve cancer therapy; mechanisms and examples Drug Resist Updates 10 2007 207 217
7. A.R. Shoemaker, M.J. Mitten, and J. Adickes Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models Clin Cancer Res 14 2008 3268 3277
8. M.C.W. Henry, D.B. Tashjian, and C.K. Breuer Neuroblastoma update Curr Opin Oncol 17 2005 19 23
9. J.M. Maris, M.D. Hogarty, R. Bagatell, and S.L. Cohn Neuroblastoma Lancet 369 2007 2106 2120
10. M.M. van Noesel, and R. Versteeg Pediatric neuroblastomas: genetic and epigenetic 'Danse Macabre' Gene 325 2004 1 15
11. J.M. Maris Medical progress: recent advances in neuroblastoma N Engl J Med 362 2010 2202 2211
12. S.W. Fesik Promoting apoptosis as a strategy for cancer drug discovery Nat Rev Cancer 5 2005 876 885
13. J.C. Reed, and M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood 106 2005 408 418
14. C. Adida, D. Berrebi, M. Peuchmaur, M. Reyes-Mugica, and D.C. Altieri Anti-apoptosis gene, survivin, and prognosis of neuroblastoma Lancet 351 1998 882 883
15. A. Islam, H. Kageyama, and N. Takada High expression of Survivin, mapped to 17q25;is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma Oncogene 19 2000 617 623
16. F. Lamers, I. van der Ploeg, and L. Schild Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe Endocr Related Cancer 18 2011 657 668
17. T. Van Maerken, L. Ferdinande, and J. Taildeman Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53 J Natl Cancer Inst 101 2009 1562 1574
18. G. Giaccone, P. Zatloukal, and J. Roubec Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer J Clin Oncol 27 2009 4481 4486
19. F. Lamers, L. Schild, and J. Koster Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression Eur J Cancer 2011 PMID: 22088485
20. K.D. Lewis, W. Samlowski, and J. Ward A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma Invest New Drugs 29 2011 161 166
21. T. Nakahara, M. Takeuchi, and I. Kinoyama YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts Cancer Res 67 2007 8014 8021
22. T. Satoh, I. Okamoto, and M. Miyazaki Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors Clin Cancer Res 15 2009 3872 3880
23. A.W. Tolcher, A. Mita, and L.D. Lewis Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin J Clin Oncol 26 2008 5198 5203
24. J.C. Hoehner, F. Hedborg, H.J. Wiklund, L. Olsen, and S. Pahlman Cellular death in neuroblastoma - in-situ correlation of apoptosis and Bcl-2 expression Int J Cancer 62 1995 19 24
25. J.C. Hoehner, C. Gestblom, and F. Hedborg A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage Lab Invest 75 1996 659 675
26. J.C. Hoehner, F. Hedborg, and L. Eriksson Developmental gene expression of sympathetic nervous system tumors reflects their histogenesis Lab Invest 78 1998 29 45
27. K.C. Goldsmith, B.J. Lestini, and M. Gross Et al BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists Cell Death Differ 17 2010 872 882
28. B.J. Lestini, K.C. Goldsmith, and M.N. Fluchel Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists Cancer Biol Ther 8 2009 1587 1595
29. T.S. Lin New agents in chronic lymphocytic leukemia Curr Hematol Malig Rep 5 2010 29 34
30. S. Ackler, Y. Xiao, and M.J. Mitten ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo Mol Cancer Ther 7 2008 3265 3274
31. R. Lock, H. Carol, and P.J. Houghton Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program Pediatric Blood Cancer 50 2008 1181 1189
32. J.J. Molenaar, M.E. Ebus, and J. Koster Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma Cancer Res 68 2008 2599 2609
33. U. Maurer, C. Charvet, A.S. Wagman, E. Dejardin, and D.R. Green Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1 Mol Cell 21 2006 749 760
34. K. Yamamoto, H. Ichijo, and S.J. Korsmeyer BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M Mol Cell Biol 19 1999 8469 8478
35. J. Hagenbuchner, M.J. Ausserlechner, and V. Porto The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression J Biol Chem 285 2010 6904 6912
36. K. De Preter, J. Vandesompele, and P. Heimann Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes Genome Biol 7 2006 R84
37. V.D. Moore, J.R. Brown, and M. Certo Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 J Clin Invest 117 2007 112 121
38. M.F. Van Delft, A.H. Wei, and K.D. Mason The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 10 2006 389 399
39. L.M. High, B. Szymanska, and U. Wilczynska-Kalak The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs Mol Pharmacol 77 2010 483 494
40. S. Ackler, M.J. Mitten, and K. Foster The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo Cancer Chemother Pharmacol 66 2010 869 880
41. P. Imming, C. Sinning, and A. Meyer Drugs, their targets and the nature and number of drug targets (vol 5, pg. 821, 2006) Nat Rev Drug Discovery 6 2007 126
42. M. Castedo, J.L. Perfettini, and T. Roumie Cell death by mitotic catastrophe: a molecular definition Oncogene 23 2004 2825 2837